BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders

A method of identifying and treating CNS-related conditions, comprising:

• obtaining a biological sample from the patient with the CNS-related condition and determining if the biological sample has an increase in one or more branched-chain amino acids (BCAAs) or metabolites thereof, when compared to a sample from a subject without the CNS-related condition;
• and
• administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and dementia selected from the group consisting of vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy, neuropsychiatric disorders, generalized anxiety disorder, social anxiety disorder, specific phobias and separation anxiety disorder, depression disorders, clinical depression (major depression), bipolar depression, persistent depressive disorder (dysthymia), seasonal affective disorder, atypical depression, treatment-resistant depression, psychotic depression, postpartum depression, premenstrual dysphoric disorder, and situational depression (stress response syndrome).

A method for treating a patient with a CNS-related condition that comprises an increase in one or more branched-chain amino acids (BCAAs) or metabolites thereof, the method comprising the steps of:

• performing or having performed an assay from a biological sample from the patient with the CNS-related condition to determine if the biological sample has an increase in one or more branched-chain amino acids (BCAAs) or metabolites thereof, when compared to a sample from a subject without the CNS-related condition;
• and
• if the biological sample from the patient with the CNS-related condition has an increase in the one or more BCAAs or metabolites thereof, then:
• treating the patient with an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and dementia selected from the group consisting of vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy, neuropsychiatric disorders, generalized anxiety disorder, social anxiety disorder, specific phobias and separation anxiety disorder, depression disorders, clinical depression (major depression), bipolar depression, persistent depressive disorder (dysthymia), seasonal affective disorder, atypical depression, treatment-resistant depression, psychotic depression, postpartum depression, premenstrual dysphoric disorder, and situational depression (stress response syndrome).